Latest Ratios: P/E Ratio -0.3x · EV/EBITDA N/A · ROE -312.8%. (2008–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $9M | $19M | $4M | $3M | $6M | $15M | $48M | $10M | $9M | $13M | $18M |
| Enterprise Value | $4M | $14M | $4M | $904049 | $4M | $-12635971 | $41M | $10M | $19M | $22M | $28M |
| P/E Ratio → | -0.32 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 8.60 | 18.69 | 235.35 | 20.12 | 18.25 | 30.73 | — | 0.25 | 0.30 | 0.32 | 0.44 |
| P/B Ratio | 0.48 | 1.73 | — | — | — | 0.67 | 16.02 | — | 1.10 | 1.15 | 1.34 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 13.62 | 234.35 | 6.12 | 10.25 | -26.13 | — | 0.25 | 0.61 | 0.54 | 0.68 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | 100.0% | -6027.9% | 100.0% | — | 80.5% | 2.6% | 4.9% | 8.0% |
| Operating Margin | -1584.4% | -1584.4% | -63617.9% | -12714.5% | -8478.3% | -5187.4% | — | -11.6% | -10.0% | -6.1% | -6.3% |
| Net Profit Margin | -1611.3% | -1611.3% | -39929.3% | -12741.6% | -8508.3% | -5170.5% | — | -12.0% | -22.3% | -16.4% | -21.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -312.8% | -312.8% | — | — | -302.0% | -197.8% | -4845.9% | -156.2% | -69.4% | -54.1% | -50.8% |
| ROA | -182.5% | -182.5% | -181.4% | -334.5% | -171.0% | -135.2% | -604.0% | -32.7% | -22.9% | -21.3% | -24.0% |
| ROIC | -456.2% | -456.2% | — | — | — | — | — | -43.5% | -11.9% | -8.5% | -7.3% |
| ROCE | -306.2% | -306.2% | — | — | -297.4% | -196.3% | -8204.4% | -67.6% | -19.1% | -13.7% | -11.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | — | — | — | 0.01 | 0.12 | — | 1.25 | 0.84 | 0.76 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.47 | — | — | — | -1.24 | -2.32 | — | 1.19 | 0.80 | 0.74 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | -842.06 | -28.91 | -8.05 | — | — |
Net cash position: cash ($5M) exceeds total debt ($46573)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.50 | 3.50 | 0.66 | 0.86 | 0.66 | 4.30 | 1.62 | 0.01 | 0.10 | 0.12 | 0.15 |
| Quick Ratio | 3.50 | 3.50 | 0.66 | 0.86 | 0.66 | 4.30 | 1.62 | -0.11 | 0.08 | 0.09 | 0.10 |
| Cash Ratio | 1.25 | 1.25 | 0.05 | 0.41 | 0.37 | 4.12 | 1.56 | 0.01 | 0.04 | 0.03 | 0.02 |
| Asset Turnover | — | 0.07 | 0.01 | 0.03 | 0.06 | 0.02 | — | 1021.63 | 1.03 | 1.37 | 1.25 |
| Inventory Turnover | 22.39 | — | — | — | — | — | — | 22.39 | 89.32 | 85.53 | 71.13 |
| Days Sales Outstanding | — | — | 14933.88 | 1942.42 | 748.17 | — | — | 2.01 | 3.86 | 4.19 | 4.59 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $4M | $655240 | $129773 | $24705 | $9962 | $3823 | $109 | $55 | $39 | $34 |
Imminent liquidity and dilution
According to current market data, the company trades at a price-to-sales ratio of 8.60, which appears to be a speculative premium rather than a reflection of fundamental earning power, given the binary and non-recurring nature of the firm's reported milestone-based revenue streams.
The P/S multiple of 8.60 suggests that investors are pricing the company based on the potential of the FHAB platform rather than any tangible commercial success. This valuation appears disconnected from the company's negative book value, indicating that the market is essentially valuing the firm as a high-risk option on future clinical data readouts.
As reported in financial statements, the company's return on equity has remained deeply negative, frequently exceeding -100% in recent quarters, which highlights a persistent inability to generate returns on invested capital while the firm continues to burn through its limited cash reserves.
The consistent decay in ROE is a direct consequence of the company's high-cost R&D model and the lack of a sustainable revenue base. This trend suggests that capital is being consumed to fund survival rather than to build a compounding asset base, which warrants significant caution for long-term investors.
Based on the 2025Q3 balance sheet, the current ratio has deteriorated to a precarious 0.26, indicating that the company's liquid assets are insufficient to cover its short-term obligations, a trend that warrants immediate concern regarding the firm's ability to maintain its current clinical trial operations.
The rapid decline in the current ratio from 2.15 in 2025Q1 to 0.26 in 2025Q3 underscores the severity of the company's liquidity crunch. This level of liquidity suggests that the firm is likely facing an imminent need for external financing, which will almost certainly result in further shareholder dilution.
While the company reports minimal debt, as evidenced by the 0.00% debt-to-equity ratio in recent filings, this lack of leverage appears to be a symptom of restricted access to credit markets rather than a sign of financial strength, leaving the firm entirely dependent on volatile equity-based funding.
Investors often misinterpret a lack of debt as a sign of a healthy balance sheet, but in the context of a clinical-stage biotech, it often signals an inability to secure traditional financing. This metric obscures the reality that the company is effectively 'leveraged' through its ongoing and necessary reliance on dilutive equity raises to cover its operating burn.
Includes 30+ ratios · 17 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SONN stock.
Sonnet BioTherapeutics Holdings, Inc.'s current P/E ratio is -0.3x. This places it at the 50th percentile of its historical range.
Sonnet BioTherapeutics Holdings, Inc.'s return on equity (ROE) is -312.8%. The historical average is -112.6%.
Based on historical data, Sonnet BioTherapeutics Holdings, Inc. is trading at a P/E of -0.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Sonnet BioTherapeutics Holdings, Inc. has -1584.4% operating margin.